Praktický průvodce Evropské asociace srdečního rytmu pro používání přímých perorálních antikoagulancií u pacientů s fibrilací síní, verze 2021.Překlad dokumentu připravený Českou kardiologickou společností

Title in English	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Translation of the document prepared by the Czech Society of Cardiology
Authors	TABORSKY Milos KAUTZNER Josef FEDORCO Marian CURILA Karol WUNSCHOVA Hanka PYSZKO Jan NOVÁK Miroslav KOZÁK Milan VALEK Martin POLASEK Rostislav KEPRT Patrik KUBICKOVA Milena PLASEK Jiri GLOGER Vit BULAVA Alan VANCURA Vlastimil SKALA Tomas PARIZEK Petr DANEK Josef
Year of publication	2023
Type	Article in Periodical
Magazine / Source	Cor et Vasa
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://e-coretvasa.cz/artkey/cor-202388-0002_2021-european-heart-rhythm-association-practical-guide-on-the-use-of-non-vitamin-k-antagonist-oral-anticoagula.php
Doi	http://dx.doi.org/10.33678/cor.2023.024
Keywords	apixaban; dabigatran; DOACs; edoxaban; NOACs; rivaroxaban
Description	New oral anticoagulants (NOACs) are globally globally mentioned in recommended practices for the treatment of fibrillation (FS) as the preferred group of anticoagulants for the prevention of stroke in patients with FS. The acronym NOAC has been in use for many years, and is used by the current recommended practices for the treatment of atrial fibrillation, which European Society of Cardiology [ESC] AF guidelines, and is almost universally accepted. Therefore, although some authors refer to this class of drugs as "direct oral anticoagulants" (direct oral anticoagulant, DOAC), we prefer to continue to use the acronym NOAC; finally, because both acronyms are interchangeable when used to refer to direct factor Xa inhibitors apixaban, edoxaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran.